← Back to home

Refractory EBV-positive diffuse large B-cell lymphoma, not otherwise specified

Clinical trials for Refractory EBV-positive diffuse large B-cell lymphoma, not otherwise specified explained in plain language.

Never miss a new study

Get alerted when new Refractory EBV-positive diffuse large B-cell lymphoma, not otherwise specified trials appear

Sign up with your email to follow new studies for Refractory EBV-positive diffuse large B-cell lymphoma, not otherwise specified, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1 Not yet finished but already full! 1

New combo may help more lymphoma patients reach potentially curative CAR-T

Disease control Recruiting now

This study tests whether giving two drugs, golcadomide and rituximab, before CAR-T cell therapy can help control aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to prior treatment. The goal is to keep the disease in check so more patients can qualify for…

Matched conditions: REFRACTORY EBV-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED

Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control

Last updated Jun 27, 2026 09:00 UTC

Refractory EBV-positive diffuse large B-cell lymphoma, not otherwise specified

Get alerted when new Refractory EBV-positive diffuse large B-cell lymphoma, not otherwise specified trials appear

New combo may help more lymphoma patients reach potentially curative CAR-T